imatinib mesylate has been researched along with Scleroderma, Diffuse in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Leon, F; Pope, J; Seney, S; Summers, KL; Vanderhoek, L; Walker, KM | 1 |
| Chung, LS; Gordon, JK; Haddon, DJ; Jarrell, JA; Spiera, RF; Utz, PJ; Wand, HE | 1 |
| Adler, AS; Benbarak, MJ; Chang, HY; Chung, L; Connolly, MK; Fiorentino, DF; Mariano, MM; Milano, A; Paniagua, RT; Ratiner, BD; Robinson, WH; Whitfield, ML; Wiskocil, RL | 1 |
| Crow, MK; Gordon, JK; Kirou, KA; Kloiber, S; Lyman, S; Magro, CM; Mehta, M; Mersten, JN; Spiera, RF; Wildman, HF | 1 |
| Jiménez, SA; Mendoza, FA | 1 |
| de Leon, F; McBain, D; Petrlich, L; Pope, J; Seney, S; Summers, K; Vanderhoek, L; Watson, S | 1 |
| Barcat, D; Bouchet, S; Chatelus, E; Chene, G; de Korwin-Krokowski, JD; Diot, E; Doussau, A; Durant, C; Ezzedine, K; Grandoulier, AS; Hachulla, E; Kostrzewa, E; Lepreux, S; Mahon, FX; Paul, C; Prey, S; Quemeneur, T; Schaeverbeke, T; Seneschal, J; Solanilla, A; Sparsa, A; Taïeb, A | 1 |
| Black, CM; Evangelou, K; Gorgoulis, VG; Katsiari, CG; Kostopoulos, C; Sfikakis, PP | 1 |
5 trial(s) available for imatinib mesylate and Scleroderma, Diffuse
| Article | Year |
|---|---|
Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
Topics: Benzamides; Cytokines; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Skin; Treatment Outcome | 2014 |
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.
Topics: Adolescent; Adult; Aged; Chemokines; Cytokines; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Proteomics; Scleroderma, Diffuse; Treatment Outcome; Young Adult | 2017 |
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
Topics: Adolescent; Adult; Aged; Benzamides; Biopsy; Dermatologic Agents; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyrimidines; Radiography; Scleroderma, Diffuse; Severity of Illness Index; Skin; Treatment Outcome; Ultrasonography; Vital Capacity; Young Adult | 2011 |
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Topics: Adult; Aged; Alopecia; Anemia; Benzamides; Diarrhea; Double-Blind Method; Early Termination of Clinical Trials; Edema; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome | 2011 |
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Topics: Adult; Aged; Benzamides; Double-Blind Method; Female; Fibrosis; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Scleroderma, Diffuse; Skin; Transforming Growth Factor beta; Treatment Outcome | 2012 |
3 other study(ies) available for imatinib mesylate and Scleroderma, Diffuse
| Article | Year |
|---|---|
Molecular framework for response to imatinib mesylate in systemic sclerosis.
Topics: Benzamides; Female; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Middle Aged; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Scleroderma, Diffuse; Skin; Young Adult | 2009 |
Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Topics: Benzamides; Early Termination of Clinical Trials; Female; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Scleroderma, Systemic | 2011 |
Imatinib for the treatment of refractory, diffuse systemic sclerosis.
Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse | 2008 |